Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1320Neoplasms 1100Carcinoma, Non-Small-Cell Lung 911Prostatic Neoplasms 741Colorectal Neoplasms 648Lung Neoplasms 611Neoplasm Metastasis 469Multiple Myeloma 444Leukemia, Myeloid, Acute 428Pancreatic Neoplasms 388Ovarian Neoplasms 387Melanoma 342Carcinoma, Hepatocellular 308Recurrence 289Brain Neoplasms 286Squamous Cell Carcinoma of Head and Neck 284Glioblastoma 259Head and Neck Neoplasms 253Stomach Neoplasms 251Precursor Cell Lymphoblastic Leukemia-Lymphoma 240Carcinoma, Renal Cell 237Triple Negative Breast Neoplasms 233Lymphoma 232Endometrial Neoplasms 221Hematologic Neoplasms 214Uterine Cervical Neoplasms 212Urinary Bladder Neoplasms 210Lymphoma, Non-Hodgkin 205Glioma 202Sarcoma 201

Interventions

Platinum 1Mitotane 1Etoposide 1Ethane 1Dichlorodiphenyldichloroethane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ENSAT Stage I Adrenal Cortex Carcinoma × 90 days × Clear all
NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

M.D. Anderson Cancer Center

Phase 3 Recruiting
240 enrolled

ENSAT Stage I Adrenal Cortex Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡